pharma · Gram-negative Bacterial Infections · SARS-CoV-2 Infection
Shionogi Inc. (U.S.)
Shionogi B.V.
Shionogi is a pharma organization headquartered in EU. Primary therapeutic focus areas include Gram-negative Bacterial Infections, SARS-CoV-2 Infection, SARS-CoV-2, Respiratory Syncytial Virus Infections, Late-onset Pomp
Florham Park, USA HQ
2001 Founded
601 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Florham Park, USA
- Founded
- 2001
- Employees
- 601
- Programs
- 6
- Drugs
- 8
- Patents
- 0
Cefiderocol
Phase 2 · small molecule · Gram-negative Bacterial Infections
Cefiderocol for Gram-negative Bacterial Infections is a Phase 2 program (small_molecule) at Shionogi B.V. with 1 ClinicalTrials.gov record(s).
Internal code 1704R2133
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Shionogi B.V.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Gram-negative Bacterial Infections
- Status
- completed
- Trials
- 1